OMC Stock Recent News

Besides Wall Street's top-and-bottom-line estimates for Omnicom (OMC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

CSW, ASAN, and others show rising P/E trends -- suggesting breakout potential backed by strong earnings surprises.

Agency Veteran and Strategic Advisor to Global Brands Will Lead Growth and Innovation Across West Coast ST. LOUIS , July 10, 2025 /PRNewswire/ -- FleishmanHillard today announced the appointment of Kristin Hollins as general manager for California.

NEW YORK , July 9, 2025 /PRNewswire/ -- Omnicom (NYSE: OMC) will publish its second quarter 2025 results on Tuesday, July 15, 2025 after the New York Stock Exchange close of trading. The company will also host a conference call to review such financial results on Tuesday, July 15, 2025, starting at 4:30 p.m.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Omnicom (OMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 29.4% upside potential for Omnicom (OMC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it has named Omnicom (NYSE: OMC) as its strategic innovation partner and agency of record to lead initiatives in support of Achieve's planning for U.S. commercial launch. “We're excited to expand our partnership with Omnicom, building on the strong foundation we've established over the past several years,” said Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.